EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

/PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company's EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2...

Related Keywords

Nicole Ruggiero ,Katie Porter ,Epivax Therapeutics Inc ,Epivax Inc ,Business Development ,Today Epivax ,Epivax Therapeutics ,